RESUMEN
To evaluate the efficacy, toxicity and factors affecting the survival rate of patients treated with irinotecan. Data from the medical records of 74 patients who had recurrent/metastatic colorectal cancer treated with single-agent irinotecan were analyzed. The mean age for all the patients was 56 years [range 19-77]. Forty-one [55%] and 33 [45%] patients had recurrent and/or metastatic colon cancer, respectively. All the patients were treated with irinotecan 350 mg/m[2] every 21 days. Grade 3-4 emesis, grade 3-4 diarrhea, grade 3-4 neutropenia and severe early cholinergic events developed in 7, 15, 7 and 1.3% of patients, respectively. One patient died due to acute renal failure. The overall response rate was 14% [complete response 5%, partial response 9%]; 61% had stable response while another 25% had progressive disease. Patients with multiple metastatic foci, patients